Alluvi, previously BI 4744, represents a promising breakthrough in obesity therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable effectiveness in clinical trials, https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/